Document is current
Any future updates will be listed below
-
Authors
Mäkinen, Ville-Petteri https://orcid.org/0000-0002-7262-2656
Kettunen, Johannes https://orcid.org/0000-0002-3345-491X
Lehtimäki, Terho https://orcid.org/0000-0002-2555-4427
Kähönen, Mika
Viikari, Jorma
Perola, Markus
Salomaa, Veikko https://orcid.org/0000-0001-7563-5324
Järvelin, Marjo-Riitta https://orcid.org/0000-0002-2149-0630
Raitakari, Olli T.
Ala-Korpela, Mika https://orcid.org/0000-0001-5905-1206
- License Information
-
More Information
Article History
Received: 26 August 2022
Revised: 7 February 2023
Accepted: 13 February 2023
First Online: 23 February 2023
Competing interests
: VS has consulted for Novo Nordisk and Sanofi and received modest honoraria from these companies. He also has ongoing research collaboration with Bayer Ltd (all unrelated to the present study). All other authors declare no competing interests.
: The NFBC, YFS and FINRISK studies were approved by the following ethical committees: Northern Ostrobothnia Hospital District, Finland; the five universities with medical schools in Finland; and the National Public Health Institute, Helsinki, Finland. All participants gave written informed consent.
